Consistent with these findings, pharmacological inhibition, or knockout of Drp1 ameliorated DKD progression as seen with reduced albuminuria, mesangial matrix expansion, and improved podocyte foot process [64,65]. This evidence concerns the gene DNM1L and diabetic kidney disease.